CALCRL Gene is a Suitable Prognostic Factor in AML/ETO⁺ AML Patients

Figure 2

(a) Quantification of CALCRL mRNAs in the BMNC bone marrow samples from patients with AML/ETO⁺ AML () or nonmalignant blood disease (). (b) Correlation between CALCRL expression and clinical phase. CALCRL mRNAs were detected in pretreated patients () and remission phase patients (). cDNAs from all samples were subjected to real-time quantitative RT-PCR analysis with primers specific for CALCRL and ABL. The ratio of the abundance of CALCRL transcripts to that of ABL transcripts (CALCRL/ABL) was calculated for statistical analysis. (c) Correlation between CALCRL expression before treatment and remission rate after the first course of induction chemotherapy.

(a)

(b)

(c)